Scotia Capital’s Alaunos Therapeutics TCRT Stock Holding History

Scotia Capital’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-69	Closed	-$37K	–	867
2021 Q1	$37K	Hold	69	–	–	﹤0.01%	788
2020 Q4	$26K	Hold	69	–	–	﹤0.01%	743
2020 Q3	$26K	Hold	69	–	–	﹤0.01%	696
2020 Q2	$34K	Hold	69	–	–	﹤0.01%	610
2020 Q1	$25K	Hold	69	–	–	﹤0.01%	620
2019 Q4	$49K	Hold	69	–	–	﹤0.01%	718
2019 Q3	$44K	Hold	69	–	–	﹤0.01%	701
2019 Q2	$60K	Hold	69	–	–	﹤0.01%	700
2019 Q1	$40K	Hold	69	–	–	﹤0.01%	684
2018 Q4	$19K	Hold	69	–	–	﹤0.01%	646
2018 Q3	$33K	Hold	69	–	–	﹤0.01%	706
2018 Q2	$40K	Hold	69	–	–	﹤0.01%	658
2018 Q1	$40K	Hold	69	–	–	﹤0.01%	689
2017 Q4	$43K	Hold	69	–	–	﹤0.01%	700
2017 Q3	$63K	Hold	69	–	–	﹤0.01%	680
2017 Q2	$64K	Buy	+69	New	+$67.6K	﹤0.01%	663

Other funds holding TCRT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

DCM

Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MVP

Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Scotia Capital's TCRT Position: Q2 2021 in Review

Scotia Capital sold out of Alaunos Therapeutics (TCRT) in Q2 2021, closing a stake of 69 shares — an estimated $37K sold.

Scotia Capital first reported a position in TCRT in Q2 2017 and held it in 16 quarters. The position peaked at $64K in Q2 2017. 155 funds tracked by Wall St. Rank hold TCRT as of Q2 2021.

Scotia Capital reported no remaining Alaunos Therapeutics position as of Q2 2021 after selling out during the quarter.
Scotia Capital sold 69 Alaunos Therapeutics shares in Q2 2021, an estimated $37K.
Scotia Capital first reported a position in Alaunos Therapeutics in Q2 2017 and held it in 16 quarters.
Scotia Capital's Alaunos Therapeutics position peaked at $64K in Q2 2017.
155 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2021.

Based on Scotia Capital's 13F filing for Q2 2021, filed 12 Aug 2021.